# A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

> **NCT00000916** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 399 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Indinavir sulfate
- **DRUG:** Lamivudine/Zidovudine
- **DRUG:** Hydroxyurea
- **DRUG:** Lamivudine
- **DRUG:** Stavudine
- **DRUG:** Zidovudine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00000916
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** 399 (—)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000916, "A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*